Trial Profile
Immunogenicity and Safety of GlaxoSmithKline Biologicals' DTPa-IPV/Hib (Infanrix-IPV+Hib) in Infants.
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 03 Oct 2021
Price :
$35
*
At a glance
- Drugs Hib-DTaP-poliovirus vaccine (Primary) ; Hib-DTaP vaccine; Poliovirus vaccine inactivated
- Indications Diphtheria; Haemophilus infections; Pertussis; Poliomyelitis; Tetanus
- Focus Adverse reactions; Pharmacodynamics
- Sponsors GlaxoSmithKline
- 17 Dec 2010 Actual end date (Nov 2010) added as reported by ClinicalTrials.gov.
- 17 Dec 2010 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 09 Jul 2010 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.